Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 19;59(4):e01938-20.
doi: 10.1128/JCM.01938-20. Print 2021 Mar 19.

A Test for the Rapid Detection of the Cefazolin Inoculum Effect in Methicillin-Susceptible Staphylococcus aureus

Affiliations

A Test for the Rapid Detection of the Cefazolin Inoculum Effect in Methicillin-Susceptible Staphylococcus aureus

Sandra Rincon et al. J Clin Microbiol. .

Abstract

The cefazolin inoculum effect (CzIE) has been associated with therapeutic failures and mortality in invasive methicillin-susceptible Staphylococcus aureus (MSSA) infections. A diagnostic test to detect the CzIE is not currently available. We developed a rapid (∼3 h) CzIE colorimetric test to detect staphylococcal-β-lactamase (BlaZ) activity in supernatants after ampicillin induction. The test was validated using 689 bloodstream MSSA isolates recovered from Latin America and the United States. The cefazolin MIC determination at a high inoculum (107 CFU/ml) was used as a reference standard (cutoff ≥16 μg/ml). All isolates underwent genome sequencing. A total of 257 (37.3%) of MSSA isolates exhibited the CzIE by the reference standard method. The overall sensitivity and specificity of the colorimetric test was 82.5% and 88.9%, respectively. Sensitivity in MSSA isolates harboring type A BlaZ (the most efficient enzyme against cefazolin) was 92.7% with a specificity of 87.8%. The performance of the test was lower against type B and C enzymes (sensitivities of 53.3% and 72.3%, respectively). When the reference value was set to ≥32 μg/ml, the sensitivity for isolates carrying type A enzymes was 98.2%. Specificity was 100% for MSSA lacking blaZ The overall negative predictive value ranged from 81.4% to 95.6% in Latin American countries using published prevalence rates of the CzIE. MSSA isolates from the United States were genetically diverse, with no distinguishing genomic differences from Latin American MSSA, distributed among 18 sequence types. A novel test can readily identify most MSSA isolates exhibiting the CzIE, particularly those carrying type A BlaZ. In contrast to the MIC determination using high inoculum, the rapid test is inexpensive, feasible, and easy to perform. After minor validation steps, it could be incorporated into the routine clinical laboratory workflow.

Keywords: BlaZ; CzIE rapid test; cefazolin inoculum effect; high inoculum.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Methodology of the CzIE rapid test. (A) Methodology of the rapid test (as described in the Materials and Methods section). (B) S. aureus quality controls. Tubes from left to right correspond to MSSA TX0117 (BlaZ-positive exhibiting the CzIE), ATCC 29213 (BlaZ-positive lacking the CzIE), and ATCC 25923 (BlaZ-negative lacking the CzIE). Change of color to red indicates a positive result (presence of CzIE), whereas a yellow color is suggestive of a negative result.
FIG 2
FIG 2
Receiver operational characteristic (ROC) curve and area under the ROC curve (AUC) to evaluate the diagnostic performance of the CzIE rapid test. (A) ROC curve for the complete set of MSSA isolates (n = 689). (B) ROC curves for BlaZ type A isolates (n = 186). The dotted lines represent random chance (AUC = 0.5).

References

    1. Arias CA, Reyes J, Carvajal LP, Rincon S, Diaz L, Panesso D, Ibarra G, Rios R, Munita JM, Salles MJ, Alvarez-Moreno C, Labarca J, Garcia C, Luna CM, Mejia-Villatoro C, Zurita J, Guzman-Blanco M, Rodriguez-Noriega E, Narechania A, Rojas LJ, Planet PJ, Weinstock GM, Gotuzzo E, Seas C. 2017. A prospective cohort multicenter study of molecular epidemiology and phylogenomics of Staphylococcus aureus bacteremia in nine Latin American countries. Antimicrob Agents Chemother 61:e00816-17. doi:10.1128/AAC.00816-17. - DOI - PMC - PubMed
    1. Hadler JL, Petit S, Mandour M, Cartter ML. 2012. Trends in invasive infection with methicillin-resistant Staphylococcus aureus, Connecticut, USA, 2001–2010. Emerg Infect Dis 18:917–924. doi:10.3201/eid1806.120182. - DOI - PMC - PubMed
    1. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, McCarthy N, Paul P, McDonald LC, Kallen A, Fiore A, Craig M, Baggs J. 2020. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med 382:1309–1319. doi:10.1056/NEJMoa1914433. - DOI - PMC - PubMed
    1. Jackson KA, Gokhale RH, Nadle J, Ray SM, Dumyati G, Schaffner W, Ham DC, Magill SS, Lynfield R, See I. 2020. Public health importance of invasive Methicillin-sensitive Staphylococcus aureus infections: surveillance in 8 US counties, 2016. Clin Infect Dis 70:1021–1028. doi:10.1093/cid/ciz323. - DOI - PMC - PubMed
    1. Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdanpanah Y, Andremont A, Duval X, Lescure FX. 2018. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect 24:125–132. doi:10.1016/j.cmi.2017.07.003. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources